Cancer Studies
Cancer prevention
- Preclinical and early clinical development of novel cancer chemopreventive agents
- Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy
- Translation of candidate biomarkers to clinical use.
- Use of high resolution LC-MS in the discovery and verification of biomarkers.
- Investigation of protein quantification using Ion mobility.
- Translation of candidate biomarkers to clinical use.
- Use of high resolution LC-MS in the discovery and verification of biomarkers.
- Investigation of protein quantification using Ion mobility.
Dr Alessandro Rufini
- Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
- Investigating and exploiting metabolic vulnerabilities in carcinogenesis
- Using circulating cell-free DNA for early detection of cancer
Professor Anne Thomas
- The design and delivery of early phase clinical studies including chemoprevention strategies
- Improving information exchange in oncology consultations
- Determine which repetitive elements are active in precancerous and cancerous cells
- Understanding what causes activation of repetitive elements
- Establish activation of which repetitive elements plays functional roles in cancer
- Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy
Liquid biopsy for early detection and stratification of cancer
Professor Martin Dyer
- Molecular cytogenetics of lymphoid malignancies
- Antibody therapy of lymphoid malignancies
- Development and assessment of novel agents for therapy of B-cell malignancies
- Analysis of circulating cancer biomarkers through liquid biopsy
- Molecular approaches to aid early detection of cancer
- Molecular mechanisms of resistance to targeted therapy
- Utility of artificial intelligence for early detection and improving therapy stratification
- Analysis of circulating endometrial cancer biomarkers through liquid biopsy
- Robotic surgery for management of endometrial cancer
- Patient-initiated follow up for low-risk endometrial cancer
- Use of ex-vivo models for personalising therapies
Dr Alessandro Rufini
- Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
- Investigating and exploiting metabolic vulnerabilities in carcinogenesis
- Using circulating cell-free DNA for early detection of cancer
- Analysis of circulating cancer biomarkers through liquid biopsy
- Molecular approaches to aid early detection of cancer
- Molecular mechanisms of resistance to targeted therapy
Personalised treatment in B cell malignancies
- Developing new diagnostic and therapeutic approaches in T-cell lymphoma
- Targeting the microenvironment in B-cell lymphoma
Professor Martin Dyer
- Molecular cytogenetics of lymphoid malignancies
- Antibody therapy of lymphoid malignancies
- Development and assessment of novel agents for therapy of B-cell malignancies
- Delivery of Phase I portfolio across haematological malignancies and solid tumours
- Therapeutic drug development
- Development and assessment of novel agents in the treatment of B-cell malignancies
Personalised medicine
Professor Martin Dyer
- Molecular cytogenetics of lymphoid malignancies
- Antibody therapy of lymphoid malignancies
- Development and assessment of novel agents for therapy of B-cell malignancies
Professor Dean Fennell
- Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers
- Analysis of circulating cancer biomarkers through liquid biopsy
- Molecular approaches to aid early detection of cancer
- Molecular mechanisms of resistance to targeted therapy
- Utility of artificial intelligence for early detection and improving therapy stratification
- Translation of candidate biomarkers to clinical use.
- Use of high resolution LC-MS in the discovery and verification of biomarkers.
- Investigation of protein quantification using Ion mobility.
- Translation of candidate biomarkers to clinical use.
- Use of high resolution LC-MS in the discovery and verification of biomarkers.
- Investigation of protein quantification using Ion mobility.
Professor Bruno Morgan
- Imaging applications to monitor drug therapy
- Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT
- Personalising breast cancer treatment according to predicted toxicity
- Radiogenomics and biomarkers
- Breast surgery and reconstuction
- Patients' views on breast cancer treatment and predictive testing
- Analysis of circulating cancer biomarkers through liquid biopsy
- Molecular approaches to aid early detection of cancer
- Molecular mechanisms of resistance to targeted therapy
Professor Anne Thomas
- The design and delivery of early phase clinical studies including chemoprevention strategies
- Improving information exchange in oncology consultations
- Delivery of Phase I portfolio across haematological malignancies and solid tumour
- Therapeutic drug development
- Development and assessment of novel agents in the treatment of B-cell malignancies
Pre clinical models enabling drug and biomarker discovery
Professor Martin Dyer
- Molecular cytogenetics of lymphoid malignancies
- Antibody therapy of lymphoid malignancies
- Development and assessment of novel agents for therapy of B-cell malignancies
- Analysis of circulating endometrial cancer biomarkers through liquid biopsy
- Molecular profiling for improved stratification to immunotherapies
- Robotic surgery for management of endometrial cancer
- Patient-initiated follow up for low-risk endometrial cancer
- Use of ex-vivo models for personalising therapies
- Mechanisms of RAS/RAF oncogene induced tumour development
- RAF/MAPK signalling in normal and cancer cells
- Ex vivo patient relevant drug testing platforms
Dr Alessandro Rufini
- Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
- Investigating and exploiting metabolic vulnerabilities in carcinogenesis
- Using circulating cell-free DNA for early detection of cancer
Professor Anne Thomas
- The design and delivery of early phase clinical studies including chemoprevention strategies
- Improving information exchange in oncology consultations
- Determine which repetitive elements are active in precancerous and cancerous cells
- Understanding what causes activation of repetitive elements
- Establish activation of which repetitive elements plays functional roles in cancer
- Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy